3rd Quarter - Report
ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021 Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines S. 3799 - PREVENT Pandemics Act Issues related to the development, manufacture, and distribution of coronavirus vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES L ERVIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.